Administer intramuscularly (IM) into a large muscle mass (e.g., gluteus maximus). Ensure aseptic technique. Intravenous (IV) administration should be reserved for hospital settings under close monitoring.

Visnidab selectively inhibits cyclooxygenase-2 (COX-2), an enzyme involved in the synthesis of prostaglandins. Prostaglandins are mediators of inflammation, pain, and fever. By inhibiting COX-2, Visnidab reduces prostaglandin production, leading to anti-inflammatory, analgesic, and antipyretic effects.

• •Known hypersensitivity to visnidab, aspirin, or other NSAIDs
• •History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• •Active gastrointestinal bleeding or peptic ulcer
• •Severe hepatic or renal impairment
• •Severe heart failure
• •Third trimester of pregnancy
• •Coronary artery bypass graft (CABG) surgery (peri-operative pain)

Store below 30°C. Protect from light. Do not freeze. Keep out of reach of children.

Symptoms of overdose may include drowsiness, nausea, vomiting, epigastric pain, GI bleeding, hypertension, acute renal failure, respiratory depression, and coma. Management is primarily supportive. There is no specific antidote. Gastric decontamination is not relevant for injectable forms. Monitor vital signs and provide symptomatic treatment.

PREGNANCY: Avoid use during the third trimester of pregnancy due to potential for premature closure of the fetal ductus arteriosus and increased risk of maternal and fetal bleeding. Use during earlier trimesters should only be if the potential benefit outweighs the potential risk. LACTATION: Visnidab is likely excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.